69947-09-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyanocyclohexanone Cyclic Ethylene Acetal is used as a key intermediate in the preparation of 1,2-dihydroquinolin-2-one and 1,2-dihydroquinoxalin-2-one derivatives, which are known for their antibacterial properties. These derivatives are used in the development of new antibiotics to combat bacterial infections.
Additionally, 4-Cyanocyclohexanone Cyclic Ethylene Acetal is used in the synthesis of heterocyclic sulfonamides, which are oral GlyT1 inhibitors. GlyT1 inhibitors are a class of drugs that target the Glycine Transporter Type 1 (GlyT1), playing a crucial role in the regulation of glycine levels in the brain. These inhibitors are being studied for their potential therapeutic applications in neurological disorders such as schizophrenia and obsessive-compulsive disorder.

InChI:InChI=1/C9H13NO2/c10-7-8-1-3-9(4-2-8)11-5-6-12-9/h8H,1-6H2

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 30482-25-8 (1,4-dioxa-spiro[4.5]dec-8-yl)-methyl-amine 
• 5697-44-9 p-tolylsulfonylmethyl isocyanide 
• 19158-51-1 P-toluenesulfonyl cyanide 
• 164987-79-5 1,5-Dibromopentan-3-one ethylene ketal 

Downstream Products

• 423116-18-1 2-[(4-oxocyclohexyl)methyl]isoindoline-1,3-dione 
• 423116-19-2 2-{[4-(hydroxyimino)cyclohexyl]methyl}isoindoline-1,3-dione 
• 423116-20-5 2-{[4-(prop-2-enyloxyimino)cyclohexyl]methyl}isoindoline-1,3-dione 
• 916159-85-8 8-(cyclopropylmethyl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile 
• 34916-10-4 4-cyanocyclohexanone 
• 40213-46-5 4-[dimethylaminomethyl]-cyclohexanone 
• 1158753-35-5 [1-methyl-1-(4-oxo-cyclohexyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Empirical Guidelines for the Development of Remote Directing Templates through Quantitative and Experimental Analyses

The ability to differentiate and selectively activate remote C-H bonds represents a perennial challenge in the field of C-H activation. Since its first report in 2012, a now-established "directing template"(DT) approach remains demonstrably effective for the functionalization of remote C-H bonds. As selectivity is hypothesized to be principally determined by the optimal positioning of the reactive catalyst to a target C-H bond, a DT's spatial factors are particularly important toward achieving high selectivity, though a systematic study on its requisite factors remain unelucidated. Through an in-depth analysis of 119 structurally unique published remote DTs, this report summarizes the key factors that are central toward achieving high selectivity at defined aryl positions, which are experimentally corroborated through the development of new aliphatic meta and para-selective DTs for electronically unbiased arenes. These empirical rules, which summarize key distance and geometric factors, are expected to be useful tools for the future development of site-selective arene C-H activation as well as other reactions that rely on covalent/noncovalent DT-mediated remote regioselection.

Abolishing Dopamine D2long/D3Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H2Receptor Agonists

3-(2-Amino-4-methylthiazol-5-yl)propyl-substituted carbamoylguanidines are potent, subtype-selective histamine H2receptor (H2R) agonists, but their applicability as pharmacological tools to elucidate the largely unknown H2R functions in the central nervous system (CNS) is compromised by their concomitant high affinity toward dopamine D2-like receptors (especially to the D3R). To improve the selectivity, a series of novel carbamoylguanidine-type ligands containing various heterocycles, spacers, and side residues were rationally designed, synthesized, and tested in binding and/or functional assays at H1-4and D2long/3receptors. This study revealed a couple of selective candidates (among others31and47), and the most promising ones were screened at several off-target receptors, showing good selectivities. Docking studies suggest that the amino acid residues (3.28, 3.32, E2.49, E2.51, 5.42, and 7.35) are responsible for the different affinities at the H2- and D2long/3-receptors. These results provide a solid base for the exploration of the H2R functions in the brain in further studies.

Preparation method of tert-butyl-8-oxo-2-azaspiro-[4.5] decane-2-formate

The invention relates to a preparation method of tert-butyl-8-oxo-2-azaspiro-[4.5] decane-2-formate, and mainly aims to solve the technical problems of high raw material cost, difficulty in reaction control, inconvenience in experimental operation and the like in an existing synthesis process. According to the method, tert-butyl-8-oxo-2-azaspiro-[4.5] decane-2-formate is prepared from cheap and easily available 1, 4-dioxaspiro [4.5] decane-8-one as an initial raw material through four steps of reaction. The reaction formula is shown in the specification. The tert-butyl-8-oxo-2-azaspiro-[4.5] decane-2-formate obtained in the invention is a useful intermediate or product synthesized from a plurality of medicines.

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

NOVEL COMPOUNDS FOR USE IN CANCER

It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures of stereoisomers, wherein X, L,R1, R 2, and R 3 are as defined herein, which are cancer cell differentiation inducing agents. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, in particular by cell differentiation therapy.

Novel method for synthesis of compound 1-cyclopropyl-1-cyano-4-cyclohexanone

The invention discloses a novel method for synthesis of a compound 1-cyclopropyl-1-cyano-4-cyclohexanone. The method comprises that p-toluenesulfonylmethyl isocyanide and a compound 1, 4-dioxospiro[4, 5]decane-8-one shown in the formula 1 undergo a reacti

Azabenzimidazole derivative having AMPK-activating activity

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, or substituted or unsubstituted alkyl, R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R1, R2 and R3 are not simultaneously hydrogen, X is a single bond, —S—, —O—, —NR5—, —C(═O)— or the like, R5 is hydrogen, or substituted or unsubstituted alkyl, Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.

Non-reductive decyanation reactions of disubstituted malononitrile derivatives promoted by NaHMDS

A new method for achieving the decyanation of disubstituted malononitrile derivatives without using reducing agents has been developed. Treatment of a six-membered malononitrile derivative with NaHMDS followed by methanol afforded the corresponding acetonitrile derivative in high yield. The present method was applicable to the decyanation reactions of a variety of malononitriles including four- and five-membered compounds as well as acyclic ones.